Abstract
The cholecystokinin (CCK) system, which has been shown to interact with both the panicogenic and respiratory systems, provides an interesting mechanism to further evaluate the central chemoreceptor and its effect on panic attack sensitivity. Intravenous CCK, a naturally occurring neuropeptide in the brain, has been found to induce the emotional and somatic symptoms of panic in both Panic Disorder (PD) and Normal Control (NC) subjects in a dose-dependent and reproducible fashion. To induce these effects, lower doses of intravenous CCK are required in the PD patients, relative to the NC subjects potentially suggesting that endogenous alterations in the CCK system may be contributing to the development of PD.
Intravenous administration of CCK-4 in association with panic also results in subjective dyspnea, that is, diminution in vital capacity without an effect on the respiratory resistance. CCK-4 also causes a significant increase in tidal volume and minute ventilation but has no effect on breathing frequency. These observations suggest that a CCK-B receptor agonist may be acting as a respiratory stimulant, exerting its effect on anxiety through a direct effect on respiration.
This study represents an examination of the specific effects of CCK-4 on the central chemoreceptor response.
The study used a modified rebreathing technique, which accurately measures the ventilatory response to carbon dioxide in terms of both threshold and sensitivity. This technique requires the subject to rebreathe from a bag containing a hyperoxic and hypercapnic gas mixture resulting in rapid equilibration between alveolar gas and arterial blood. Use of a hyperoxic gas allows for the preferential examination of the central chemoreflexes (sensitive to CO2) with little if any effect of the peripheral (oxygen sensitive) chemoreflexes.
After significant training, 15 healthy control subjects were assigned via a double blind procedure to receive an intravenous injection of placebo or CCK-4, using a between-subjects design. A between-subjects comparison was undertaken for the injection run (run #3) between subjects receiving the CCK-4 injection and those receiving the placebo injection. As well, a within-subject comparison was undertaken to compare the results of the run following the injection (run #3) vs. the previous run when no injection took place (run #2).
No significant differences were noted between subjects who received CCK-4 as compared with placebo for: basal or sub-threshold ventilation, threshold CO2 resulting in a change in ventilation, or sensitivity of the central chemoreflex, regardless of whether a panic attack did or did not take place. In addition, within the group receiving the CCK-4 challenge, no significant differences were noted during run #3 (received the CCK-4 injection) and a prior run where no injection took place (run #2).
We conclude that CCK-4 does not act to induce panic by altering the central (CO2 sensitive) chemoreceptor.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bates JH, Bradwejn J . (1995): Ventilatory response to cholecystokinin tetrapeptide in anaesthetized dogs. Neuroreport 6: 2513–2517
Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S, Karkanias C . (1992): A dose-ranging study of the behavioural and cardiovascular effects of CCK-tetrapeptide-induced in panic disorder. Biological Psychiatry 32: 903–912
Bradwejn J, Koszycki D, Bourin M . (1991a): Dose ranging study of cholecystokinin in healthy volunteers. J Psychiatr Neurosci 16: 91–95
Bradwejn J, Koszycki D, Shriqui C . (1991b): Enhanced sensitivity to cholecystokinin-tetrapeptide in PD: clinical and behavioral findings. Arch Gen Psychiatry 48: 603–607
Bradwejn J, LeGrand JM, Koszycki D, Bates JH, Bourin M . (1998): Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry 55: 280–282
Bourin M, Malinge M, Vasar E, Bradwejn J . (1995): Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol 10: 116–126
Coplan JD, Klein DF . (1996): Pharmacological probes in panic disorder. In Westenberg HGM, Den Boer JA, Murphy D (eds), Advances in the Neurobiology of Anxiety Disorders. New York, John Wiley and Sons Ltd.
Duffin J, Mohan R, Vasiliou P, Stephenson R, Mahamed S . (2000): A model of the chemoreflex control of breathing in humans: model parameter measurement. Resp Physiology 120: 13–26
Duffin J, McAvoy GV . (1988): The peripheral-chemoreceptor threshold to CO2 in man. J Physiol (Lond) 406: 15–26
Gardner WN . (1996): The pathophysiology of hyperventilation disorders. Chest 109: 516–534
Gillis RA, Quest JA, Pagani FD, Souza JD, Da Silva AM, Jensen RT, Garvey TQ 3d, Hamosh P . (1983): Activation of central nervous system cholecystokinin receptors stimulates respiration in the cat. J Pharmacol Exp Ther 224: 408–414
Gorman JM, Kent J, Martinez J, Browne S, Coplan J, Papp LA . (2001): Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression and premenstrual dysphoric disorder: evidence for a central fear mechanism. Arch Gen Psychiatry 58: 125–135
Harro J, Vasar E, Koszycki D, Bradwejn J . (1995): Cholecystokinin in panic anxiety disorders. Advances in Biology Psychiatry 1: 235–262
Hurlé MA, Dierssen MM, Morin-Surun MP, Oceja C, Flórez J . (1988): Respiratory actions induced by cholecystokinin at the brainstem level. Peptides 9: 809–815
Klein DF . (1993): False suffocation alarms, spontaneous panics, and related conditions. Arch Gen Psychiatry 50: 306–317
Mahamed S, Ali AF, Ho D, Wang B, Duffin J . (2001): The contribution of chemoreflex drives to resting breathing in man. Exp Physiol 86: 109–116
Mahamed S, Duffin J . (2001): Repeated hypoxic exposures change respiratory chemoreflex control in humans. J Physiol 534: 595–603
Mohan R, Duffin J . (1997): The effect of hypoxia on the ventilatory response to carbon dioxide in man. Respir Physiol 108: 101–115
Nutt D, Lawson C . (1992): Panic attacks — a neurochemical overview of models and mechanisms. Br J Psychiatry 160: 165–178
Pagani FD, Taveira da Silva AM, Hamosh P, Garvey TQ 3d, Gillis RA . (1982): Respiratory and cardiovascular effects of intraventricular cholecystokinin. Eur J Pharmacol 78: 129–132
Pain MCF, Biddle N, Tiller JWG . (1988): Panic disorder, ventilatory response to CO2’s respiratory variables. Psychosom Med 50: 541–548
Papp LA, Klein DF, Gorman JM . (1993a): CO2 hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry 150: 1149–1157
Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz MR, Hollander E, Fyer AJ, Jordan F, Gorman JM . (1993b): Diagnostic and substance specificity of CO2-induced panic. Am J Psychiatry 150: 250–257
Papp LA, Martinez JM, Klein DF, Coplan JD, Gorman JM . (1995): Rebreathing tests in panic disorder. Biol Psychiatry 38: 240–245
Perna G, Battaglia M, Garberi A, Arancio C, Bertani A, Bellodi L . (1994): CO2/O2 challenge test in panic disorder. Psychiatry Res 42: 159–171
Perna G, Berani A, Caldirola D, Bellodi L . (1996): Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Am J Psychiatry 153: 1060–1064
Read DJC . (1967): A clinical method for assessing the ventilatory response to CO2 . Austral Ann Med 16: 20–32
Shlik J, Vasar V, Aluoja A, Kingisepp PH, Jagomägi K, Vasar E, Rägo L, Bradwejn J . (1997): The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry 42: 206–212
Sinha SS, Coplan JD, Pine DS, Martinez JA, Klein DF, Gorman JM . (1999): Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res 86: 93–98
Verburg K, Griez E, Meijer J, Pols H . (1995): Discrimination between panic disorder and generalized anxiety disorder by 35% CO2 challenge. Am J Psychiatry 152: 1081–1083
Acknowledgements
We would like to thank Mr. Lukasz Struzik for his considerable assistance with the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Data presented: American Psychiatric Association Annual Meeting “The Clinician” Washington DC. May 15–20.
Rights and permissions
About this article
Cite this article
Katzman, M., Duffin, J., Shlik, J. et al. The Ventilatory Response to Cholecystokinin Tetrapeptide in Healthy Volunteers. Neuropsychopharmacol 26, 824–831 (2002). https://doi.org/10.1016/S0893-133X(02)00283-X
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(02)00283-X
